MYOPIA MANAGEMENT 2050

#TURNPOINT 2050

Red light therapy is the best way to treat myopia

≈ 50%2050

Turning Point 2050.
Evidence. The bigger picture.

Check out the entire website - here, without leaving the professor's website. Explore research, learn about methods, and see what today's decisions mean for children's adult lives.

Open Punkt Zwrotny 2050 Read Professor's manifesto
punktzwrotny2050.pl↗

You can scroll and browse the page in this window. Copy from 12.09.2026 . Open current website ↗

#PunktZwrotny2050 · Myopia Management · Expert Position Paper

Red light therapy is the best way to treat myopia

Turning point: red light therapy plus defocusing lenses - an absolute game changer in the fight against the myopia pandemic

Ladies and gentlemen, professional colleagues,

The predictions of the World Health Organization are clear: by 2050, nearly half of humanity will be affected by myopia. In May 2026, at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Denver ( Colorado Convention Center ), the ophthalmology and optometric community gave a clear direction. Among the many presented solutions, the combination of repetitive low-intensity red light therapy (RLRL) with advanced new generation defocusing glasses was recognized as the method to be followed in cases requiring the highest effectiveness.

Red light therapy is the best way to stop and control myopia

According to the latest guidelines of the International Myopia Institute from 2025 presented at the ARVO 2026 congress, Repeated Low-level Red Light therapy ( RLRL ) was recognized as the most effective monotherapy in the treatment and control of myopia in children, the second most effective were glasses and contact lenses with defocusing optics and orthocorrective lenses. Low doses of atropine have the least effectiveness in controlling myopia.

Why is red light therapy currently the best treatment for myopia?

Traditional atropine monotherapy without the support of defocus glasses or orthocorrective lenses does not sufficiently stop progression in many patients. Even in combination with these glasses or lenses, the effect is clearly weaker than in the case of monotherapy with repetitive low-frequency red light (RLRL). Combining atropine with red light therapy is absolutely prohibited - atropine dilates the pupil, eliminating the eye's natural defense mechanism against excessive exposure to light.

However, the combination of modern defocusing glasses (DIMS TED, HAL structures and similar) with RLRL works in two ways: the glasses provide a continuous peripheral optical signal inhibiting axis elongation, and red light (approx. 650 nm, 3 minutes twice a day) improves blood flow in the blood through photobiomodulation. choroid, eliminates scleral hypoxia and allows shortening of the eyeball. In the research presented at ARVO 2026, the use of DIMS glasses alone resulted in an average of 0,16 mm of elongation per year. After adding RLRL, the axis was shortened by – 0,13 to – 0,21 mm per year – a stronger effect than the sum of both methods used separately.

A similar mechanism is also observed when combining RLRL therapy with orthokeratotic lenses.

Red light therapy is the best treatment for myopia - evidence from a British audit

Dr. Neema Ghorbani Mojarrada from the University of Bradford, who conducted a pilot audit of the Eyerising device in the UK, summarized:

"One of the potential benefits of this device for myopia control is that the therapy takes place at home and can be administered under parental supervision. [...] There were no adverse events reported with red light therapy in the UK pilot program. [...] When patients did not remember to use the device, the monitoring software detected this and sent them reminders. The device provides a new option for a non-optical approach. It is a valuable additional tool."

Initial safety concerns have been allayed

At first, there were concerns whether the laser beam would damage the retina. However, these fears have been clearly dispelled. We are talking about low-level therapy, not an ablative laser. Thanks to the natural micro-movements of the eyeball (saccades, accommodation, micro-tremor) and biological thermoregulation processes, the energy is dissipated and there is no local overheating of the photoreceptors. Studies in animal models and real-world clinical data support safety when following the protocol. There is also more and more talk about the development of versions based on LED matrices, which further increase the safety margin.

Red light therapy is the best way to control myopia in children - the key role of adherence

A child very often takes off his glasses while playing, learning or doing everyday activities. Nobody monitors it in real time. RLRL therapy solves this problem: the device records each session, sends automatic reminders and allows the doctor to check the regularity of use. Additionally, parents who have invested in comprehensive treatment naturally care about its consistent implementation. This combination of technology and adherence psychology makes RLRL currently the most effective tool in cases of progressive myopia, regardless of the size of the defect, and especially in combination with defocusing optics.

Want to know more? Welcome to Krótkowzroczność.pl

The topic of myopia does not end with one treatment method or article. That's why I co-create Krótkowzroczność.pl - a place where we try to collect in one, organized system the knowledge needed by both parents of children with myopia and professional colleagues.

It is currently one of the most extensive and substantive Polish portals devoted exclusively to myopia: its epidemiology, diagnostics, progression, control options and scientific evidence behind individual treatment methods.

We publish there expert articles, research and scientific evidence, discuss available therapy methods and show how to translate knowledge from publications into real practice.

I especially encourage you to use the AL Calculator and the eye axial length percentile charts. This tool allows you to plot subsequent eye axial length measurements on percentile charts and observe them on the time axis. Instead of looking only at a single result, you can see the direction of change and better understand the dynamics of progression.

For those who would like a broader view of the scale of the problem, we have also prepared an extensive review of myopia epidemiology — from population data to the 2050 perspective.

Krótkowzroczność.pl has been prepared both for specialists who want to have organized sources and tools at hand, and for parents who need to understand what is actually happening with their child's vision.

If you want to go deeper into this topic - that's where I invite you.

Michał Nowak

Ladies and Gentlemen, if we do not turn away from this path, we will face a severe myopia pandemic that cannot be cured by any means. It can only be stopped by decisive, coordinated intervention - and that intervention must start today.

Either we take action now, promoting proven, synergistic treatment systems based on red light therapy, or we condemn subsequent generations to life with progressive visual impairment, retinal complications and huge health, mental and social costs that may paralyze the functioning of entire societies.

prof. dr hab. n. med. Michał Szymon Nowak AUTHOR OF THE MANIFESTO #PUNKTZWROTNY2050

This is #PunktZwrotny2050 .

Let's act.

HEREINafter Scientific Evidence

EVIDENCE BASE · RLRL

The effectiveness of myopia therapy with red light is confirmed by scientific research

Key randomized clinical trials, comparative analysis and meta-analysis of low-intensity repetitive red light therapy.

01 SYSTEMATIC REVIEW · META-ANALYSIS

Repeated low-level red-light therapy vs. conventional treatments for myopic control in children: a systematic review and meta-analysis

Li Ping Liu, Yi Shan Hu, Huai Cheng Chen, Yun Tang, Xiao Min Mao

Scientific Reports · 2025 · 15:30794 · DOI 10.1038 /s41598- 025-16868-8

A meta-analysis of seven studies showed significantly less axial length progression in the RLRL group than in groups receiving conventional myopia control methods. The authors indicated the need for further, long-term research.

NATURE / SCIENTIFIC REPORTS
02 CLINICAL TRIAL · RLRL + DIMS

Efficacy of repeated low-level red-light therapy combined with defocus incorporated multiple segments spectacles for controlling childhood myopia

Chang-Kang Luo, Chun-Yan Lai, Jia-Hao Tan, Wei Zhao, Qing-Qing Tan

Photodiagnosis and Photodynamic Therapy · 2025 · 54:104681 · PMID 40517989

After 12 months, the groups receiving RLRL showed axial shortening compared to the groups using only single vision glasses or DIMS. There were no serious adverse events related to therapy.

PUBMED
03 MULTI-CENTER RCT

Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children: A Multicenter Randomized Controlled Trial

Jiang Y, Zhu Z, Tan X, Kong X, Zhong H, Zhang J, Xiong R, Yuan Y, Zeng J, Morgan IG, He M

Ophthalmology · 2022 · 129 ( 5 ): 509–519 · DOI 10.1016 /j.ophtha. 2021.11.023

RLRL reduced myopia progression and axial lengthening compared to regular glasses.

DOI / OPHT HAL MOLOGY
04 RANDOMIZED DOUBLE BLIND

Myopia Control Effect of Repeated Low-Level Red-Light Therapy in Chinese Children: A Randomized, Double-Blind, Controlled Clinical Trial

Dong J, Zhu Z, Xu H, He M

Ophthalmology · 2023 · 130 ( 2 ): 198–204 · DOI 10.1016 /j.ophtha. 2022.08.024

The full dose of RLRL after 6 months was more effective than the device emitting 10% power.

DOI / OPHT HAL MOLOGY
05 RANDOMIZOWANE RCT · 650 NM

Six-month repeated irradiation of 650 nm low-level red light reduces the risk of myopia in children: a randomized controlled trial

Lei Tian, Kai Cao, Dong-Li Ma, Li-Xin Lu, Shi-Qiang Zhao, Ao Li, Chang-Xi Chen, Zhang-Fang Ma, Zi-Bing Jin, Chun-Rong Ma, Ying Jie

International Ophthalmology · 2023 · 43(10):3549–3558 · DOI 10.1007/s10792-023-02762-7

Six months of exposure to 650 nm light reduced eye elongation and the risk of myopia.

DOI / SPRINGS
06 RANDOMIZED RCT · 12 MONTH

Effectiveness of repeated low-level red light in myopia prevention and myopia control

Guihua Liu, Hua Rong, Yipu Liu, Biying Wang, Bei Du, Desheng Song, Ruihua Wei

British Journal of Ophthalmology · 2024 · 108(9):1299–1305 · DOI 10.1136/bjo-2023-324260

RLRL slowed progression in children with myopia and reduced the number of new cases in children with premyopia.

DOI/BJO
07RANDOMIZOWANE RCT · RLRL VS ATROPINA

Efficacy Comparison of Repeated Low-Level Red Light and Low-Dose Atropine for Myopia Control: A Randomized Controlled Trial

Yanxian Chen, Ruilin Xiong, Xu Chen, Jian Zhang, Gabriella Bulloch, Xiaoxuan Lin, Xiaoman Wu, Jinying Li

Translational Vision Science & Technology · 2022 · 11(10):33 · DOI 10.1167/tvst.11.10.33

After 12 months, RLRL controlled axial length and myopia progression more effectively than atropine 0,01%.

DOI/ARVO TVST